Akebia Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.54 |
Market Cap |
$516.24 M |
Shares Outstanding |
117.86 M |
Public Float |
103.41 M |
Address |
245 First Street Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.akebia.com |
Updated | 07/08/2019 |
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat, which is an oral therapy for the treatment of anemia due to chronic kidney disease. |